ATF3 and plasma cell myeloma: Ri et al found that in multiple myeloma (MM), patients with higher ATF3 and ATF4 expression had longer progression-free survival (PFS) than those with lower ATF3 expression; this observation was also confirmed in chromatin immunoprecipitation (Ch-IP) experiments with MM cell lines and patient specimens [9].